

# CITATION REPORT

List of articles citing

## Metabolic syndrome and non-alcoholic fatty liver disease

DOI: 10.1016/s1665-2681(19)31822-8  
Annals of Hepatology, 2009, 8, S18-S24.

**Source:** <https://exaly.com/paper-pdf/45361082/citation-report.pdf>

**Version:** 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
118	Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: association with liver fibrosis. <b>2010</b> , 59, 1327-30		82
117	Molecular signatures of nonalcoholic fatty liver disease: the present and future. <b>2010</b> , 51, 1866		
116	Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. <b>2010</b> , 40, 887-92		129
115	Latin American Association for the Study of the Liver Practice Guidelines: Diagnosis, management, and treatment of hepatitis C This document has been approved by the Latin American Association for the Study of the Liver (ALEH). <i>Annals of Hepatology</i> , <b>2010</b> , 9, S8-S26	3.1	3
114	Liver diseases in Mexico and their associated mortality trends from 2000 to 2007: A retrospective study of the nation and the federal states. <i>Annals of Hepatology</i> , <b>2010</b> , 9, 428-438	3.1	18
113	Serum fetuin A/ $\alpha$ 2HS-glycoprotein levels in patients with non-alcoholic fatty liver disease: relation with liver fibrosis. <b>2010</b> , 47, 549-53		49
112	Serum levels of osteoprotegerin in the spectrum of nonalcoholic fatty liver disease. <b>2010</b> , 70, 541-6		31
111	Contribution of adipose tissue to health span and longevity. <b>2010</b> , 37, 1-19		33
110	Metabolic syndrome predicts the incidence of hepatic steatosis in Koreans. <b>2010</b> , 4, e163-246		4
109	Treatment options for nonalcoholic fatty liver disease. <b>2010</b> , 3, 121-37		103
108	Coronary flow reserve is impaired in patients with nonalcoholic fatty liver disease: association with liver fibrosis. <b>2010</b> , 211, 182-6		70
107	Hepatitis C and metabolic syndrome. <b>2010</b> , 5, 209-215		
106	Mediterranean diet and the metabolic syndrome: the end of the beginning. <b>2010</b> , 8, 197-200		28
105	Serum osteocalcin levels in patients with nonalcoholic fatty liver disease: association with ballooning degeneration. <b>2011</b> , 71, 631-6		29
104	Serum levels of omentin, chemerin and adiponin in patients with biopsy-proven nonalcoholic fatty liver disease. <b>2011</b> , 46, 91-7		89
103	Serum pigment epithelium-derived factor levels are increased in patients with biopsy-proven nonalcoholic fatty liver disease and independently associated with liver steatosis. <b>2011</b> , 412, 2296-9		11
102	Circulating vaspin levels and epicardial adipose tissue thickness are associated with impaired coronary flow reserve in patients with nonalcoholic fatty liver disease. <b>2011</b> , 217, 125-9		45

101	The Role of the Acute-Phase Proteins in the Development and Progression of Liver Diseases. <b>2011,</b>	
100	Association between the presence of brown adipose tissue and non-alcoholic fatty liver disease in adult humans. <b>2011, 34, 318-23</b>	42
99	Epidemiology of the metabolic syndrome in the USA. <b>2011, 12, 333-40</b>	98
98	Relationship between nonalcoholic fatty liver disease and metabolic syndrome. <b>2011, 12, 125-30</b>	56
97	Serum levels of vaspin, obestatin, and apelin-36 in patients with nonalcoholic fatty liver disease. <b>2011, 60, 544-9</b>	53
96	Circulating levels of vascular endothelial growth factor A and its soluble receptor in patients with biopsy-proven nonalcoholic fatty liver disease. <b>2011, 42, 38-43</b>	12
95	Adipose triacylglycerol lipase is a major regulator of hepatic lipid metabolism but not insulin sensitivity in mice. <b>2011, 54, 146-56</b>	93
94	Serum galectin-3 levels in patients with nonalcoholic fatty liver disease. <b>2011, 44, 955-8</b>	9
93	Serum zinc- $\alpha$ -glycoprotein concentrations in patients with non-alcoholic fatty liver disease. <b>2011, 49, 93-7</b>	11
92	Gamma-glutamyl transferase is strongly associated with degree of overweight and sex. <b>2011, 52, 635-8</b>	7
91	Serum levels of hepcidin in patients with biopsy-proven nonalcoholic fatty liver disease. <b>2011, 9, 287-90</b>	35
90	Genetic effects at pleiotropic loci are context-dependent with consequences for the maintenance of genetic variation in populations. <b>2011, 7, e1002256</b>	35
89	NAFLD in the absence of metabolic syndrome: different epidemiology, pathogenetic mechanisms, risk factors for disease progression?. <b>2012, 32, 14-21</b>	44
88	Endoplasmic Reticulum Stress and the Unfolded Protein Response in Lipid Metabolism and Obesity. <b>2012, 231-256</b>	
87	Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease. <b>2012, 45, 655-8</b>	35
86	Non-alcoholic fatty liver disease and metabolic syndrome in adolescents: pathogenetic role of genetic background and intrauterine environment. <b>2012, 44, 29-40</b>	78
85	Non-alcoholic fatty liver disease across the spectrum of hypothyroidism. <b>2012, 57, 150-6</b>	177
84	Association of Alanine Aminotransferase Levels (ALT) with the Hepatic Insulin Resistance Index (HIRI): a cross-sectional study. <b>2012, 12, 16</b>	9

83	Non-Alcoholic Fatty Liver Disease (NAFLD) Is it an Emerging Risk Factor for Coronary Artery Disease?. <b>2012</b> , 1, 1-2		1
82	Body composition analysis of obesity and hepatic steatosis in mice by relaxation compensated fat fraction (RCFF) MRI. <b>2012</b> , 35, 837-43		12
81	Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis by inducing the excretion of hepatic lipids in high-fat diet-fed KK-Ay mice. <b>2012</b> , 61, 944-53		47
80	Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. <b>2013</b> , 28 Suppl 1, 68-76		170
79	Ellagic acid attenuates high-carbohydrate, high-fat diet-induced metabolic syndrome in rats. <b>2013</b> , 52, 559-68		109
78	Serum osteopontin levels as a predictor of portal inflammation in patients with nonalcoholic fatty liver disease. <b>2013</b> , 45, 58-62		18
77	Dietary management of the metabolic syndrome - one size fits all?. <b>2013</b> , 72, 310-6		4
76	Linking nonalcoholic fatty liver disease to hepatocellular carcinoma: from bedside to bench and back. <b>2013</b> , 99, 10-6		8
75	Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease. <i>Annals of Hepatology</i> , <b>2013</b> , 12, 380-387	3.1	64
74	Gallstone disease does not predict liver histology in nonalcoholic fatty liver disease. <b>2014</b> , 8, 313-7		20
73	Testosterone replacement ameliorates nonalcoholic fatty liver disease in castrated male rats. <b>2014</b> , 155, 417-28		47
72	Zonation of glucose and fatty acid metabolism in the liver: mechanism and metabolic consequences. <b>2014</b> , 96, 121-9		103
71	Risk of de novo post-transplant type 2 diabetes in patients undergoing liver transplant for non-alcoholic steatohepatitis. <b>2015</b> , 15, 175		22
70	Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk. <b>2015</b> , 33, 1207-14		53
69	Successful Treatment of Polycystic Ovarian Syndrome, Nonalcoholic Fatty Liver Disease and Infertility with Chinese Herbal Medicine: A Case Report. <b>2015</b> , 04,		4
68	Antiresistin RNA Oligonucleotide Ameliorates Diet-Induced Nonalcoholic Fatty Liver Disease in Mice through Attenuating Proinflammatory Cytokines. <b>2015</b> , 2015, 414860		6
67	Metabolic syndrome and its components as predictors of nonalcoholic fatty liver disease in a northern urban Han Chinese population: a prospective cohort study. <b>2015</b> , 240, 144-8		40
66	Non-alcoholic Fatty Liver Disease and Metabolic Syndrome-Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology. <b>2015</b> , 5, 51-68		78

65	Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research. <b>2015</b> , 59, 106-25	100
64	Nonalcoholic fatty liver disease as a risk factor of arterial stiffness measured by the cardioankle vascular index. <b>2015</b> , 94, e654	23
63	A novel animal model of metabolic syndrome with non-alcoholic fatty liver disease and skin inflammation. <b>2015</b> , 53, 1110-7	14
62	Conjugated bile acid-activated S1P receptor 2 is a key regulator of sphingosine kinase 2 and hepatic gene expression. <b>2015</b> , 61, 1216-26	114
61	Liver function as an engineering system. <b>2016</b> , 62, 3285-3297	7
60	Relationship between Non-alcoholic Fatty Liver Disease and Thyroid Dysfunction. <b>2016</b> , 55, 1941-2	2
59	NAFLD. <b>2016</b> , 8-14	1
58	Contrast-enhanced ultrasonography could be a non-invasive method for differentiating none or mild from severe fibrosis in patients with biopsy proven non-alcoholic fatty liver disease. <b>2016</b> , 51, 1126-32	9
57	Global Epidemiology of Nonalcoholic Fatty Liver Disease and Perspectives on US Minority Populations. <b>2016</b> , 61, 1214-25	98
56	De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose. <b>2016</b> , 91, 452-68	207
55	Microarray analysis of gene expression in liver, adipose tissue and skeletal muscle in response to chronic dietary administration of NDGA to high-fructose fed dyslipidemic rats. <b>2016</b> , 13, 63	10
54	The role of active brown adipose tissue in human metabolism. <b>2016</b> , 43, 355-361	18
53	Apigenin, a modulator of PPAR $\gamma$ attenuates HFD-induced NAFLD by regulating hepatocyte lipid metabolism and oxidative stress via Nrf2 activation. <b>2017</b> , 136, 136-149	102
52	Pharmacological management of non-alcoholic fatty liver disease: Atorvastatin versus pentoxifylline. <b>2017</b> , 13, 2375-2381	24
51	Aqueous calyxes extract of Roselle or Hibiscus sabdariffa Linn supplementation improves liver morphology in streptozotocin induced diabetic rats. <b>2017</b> , 18, 13-20	9
50	Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia. <b>2017</b> , 7, 45176	131
49	Elevated Neutrophil-to-Lymphocyte Ratio in Metabolic Syndrome Is Associated with Increased Risk of Colorectal Adenoma. <b>2017</b> , 15, 393-399	9
48	Low-grade inflammation and its relation to obesity and chronic degenerative diseases. <b>2017</b> , 80, 101-105	74

47	Higher platelet counts are associated with metabolic syndrome independent of fatty liver diagnosis. <b>2017</b> , 80, 125-132	12
46	Dahuang Zexie Decoction Protects against High-Fat Diet-Induced NAFLD by Modulating Gut Microbiota-Mediated Toll-Like Receptor 4 Signaling Activation and Loss of Intestinal Barrier. <b>2017</b> , 2017, 2945803	14
45	Conophylline inhibits non-alcoholic steatohepatitis in mice. <b>2017</b> , 12, e0178436	16
44	Fatty Liver Index and Lipid Accumulation Product Can Predict Metabolic Syndrome in Subjects without Fatty Liver Disease. <b>2017</b> , 2017, 9279836	9
43	Amodiaquine improves insulin resistance and lipid metabolism in diabetic model mice. <b>2018</b> , 20, 1688-1701	6
42	Annals of Hepatology: Viewpoints from Afar. <i>Annals of Hepatology</i> , <b>2018</b> , 17, 4-7	3.1
41	Reactive hyperemia index can screen endothelial dysfunction in obese subjects with non-alcoholic fatty liver disease. <b>2018</b> , 2, 39-44	
40	Association of non-alcoholic fatty liver disease with cardiovascular disease and subclinical atherosclerosis. <b>2018</b> , 14, 1233-1244	26
39	Human hepatic 3D spheroids as a model for steatosis and insulin resistance. <b>2018</b> , 8, 14297	72
38	The Clinical and Economic Burden of Nonalcoholic Steatohepatitis. <b>2018</b> , 17, 345-349	3
37	Non-alcoholic Fatty Liver Disease: A Review of Anti-diabetic Pharmacologic Therapies. <b>2018</b> , 6, 168-174	18
36	Association between nonalcoholic fatty liver disease and subclinical atherosclerosis: a cross-sectional study on population over 40 years old. <b>2018</b> , 18, 147	16
35	A Randomised Controlled Trial on the Effectiveness and Adherence of Modified Alternate-day Calorie Restriction in Improving Activity of Non-Alcoholic Fatty Liver Disease. <b>2019</b> , 9, 11232	32
34	Azoramide ameliorates fructose-induced nonalcoholic fatty liver disease in mice. <b>2019</b> , 59, 62-69	4
33	Conophylline inhibits high fat diet-induced non-alcoholic fatty liver disease in mice. <b>2019</b> , 14, e0210068	15
32	Ursodeoxycholic acid ameliorates hepatic lipid metabolism in LO2 cells by regulating the AKT/mTOR/SREBP-1 signaling pathway. <b>2019</b> , 25, 1492-1501	21
31	Dual Energy Transfer-Based Fluorescent Nanoprobe for Imaging miR-21 in Nonalcoholic Fatty Liver Cells with Low Background. <b>2019</b> , 91, 6761-6768	17
30	Development of nonalcoholic fatty liver disease model by high-fat diet in rats. <b>2019</b> , 30,	7

29	Developments in bile salt based therapies: A critical overview. <b>2019</b> , 161, 1-13		39
28	Maternally expressed gene 3 in metabolic programming. <b>2020</b> , 1863, 194396		4
27	Modeling Diet-Induced Metabolic Syndrome in Rodents. <b>2020</b> , 64, e2000249		5
26	Endothelial dysfunction in nonalcoholic steatohepatitis with low cardiac disease risk. <b>2020</b> , 10, 8825		4
25	Imaging and immunometabolic phenotyping uncover changes in the hepatic immune response in the early phases of NAFLD. <b>2020</b> , 2, 100117		3
24	Insights into the Impact of Microbiota in the Treatment of NAFLD/NASH and Its Potential as a Biomarker for Prognosis and Diagnosis. <b>2021</b> , 9,		7
23	Tetrahydroxanthohumol, a xanthohumol derivative, attenuates high-fat diet-induced hepatic steatosis by antagonizing PPAR $\alpha$ <b>2021</b> , 10,		1
22	Quantification of Liver Fat by MRI-PDFF Imaging in Patients with Suspected Non-alcoholic Fatty Liver Disease and Its Correlation with Metabolic Syndrome, Liver Function Test and Ultrasonography. <b>2021</b> , 11, 586-591		2
21	A Computational Model of Hepatic Energy Metabolism: Understanding Zonated Damage and Steatosis in NAFLD. <b>2016</b> , 12, e1005105		25
20	Diagnosing fatty liver disease: a comparative evaluation of metabolic markers, phenotypes, genotypes and established biomarkers. <b>2013</b> , 8, e76813		8
19	Characterization of liver changes in ZSF1 rats, an animal model of metabolic syndrome. <b>2017</b> , 109, 491-497		2
18	The serum vitamin D level is inversely correlated with nonalcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , <b>2016</b> , 22, 146-51	6.9	37
17	THE ROLE OF ENDOTHELIAL DYSFUNCTION IN THE PROGRESSION MECHANISMS OF NON-ALCOHOLIC STEATOHEPATITIS IN PATIENTS WITH OBESITY AND CHRONIC KIDNEY DISEASE. <i>Wiadomości Lekarskie</i> , <b>2019</b> , 72, 523-526	0.3	8
16	Combination drug treatment in patients with non-alcoholic fatty liver disease. <i>World Journal of Hepatology</i> , <b>2010</b> , 2, 139-42	3.4	18
15	Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease. <i>World Journal of Hepatology</i> , <b>2013</b> , 5, 470-8	3.4	111
14	Nonalcoholic fatty liver disease. 658-674		
13	Noninvasive markers: a double-edged sword that stratifies nonalcoholic steatohepatitis. <i>Clinical and Molecular Hepatology</i> , <b>2013</b> , 19, 116-9	6.9	
12	CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE. <i>Journal of Evolution of Medical and Dental Sciences</i> , <b>2013</b> , 2, 6584-6593	0.1	

11	Effects of Dietary Fructose and Glucose on Hepatic Steatosis and NLRP3 Inflammasome in a Rodent Model of Obesity and Type 2 Diabetes. <i>Journal of the Korean Society of Food Science and Nutrition</i> , <b>2013</b> , 42, 1576-1584	1.5	
10	Association between Serum Fibroblast Growth Factor-21 Levels and Nonalcoholic Fatty Liver in Korean Men with Type 2 Diabetes. <i>Korean Journal of Medicine</i> , <b>2015</b> , 88, 273	0.5	
9	Impact of qualitative endoscopic ultrasonography on fatty pancreas at a referral medical center.. <i>JGH Open</i> , <b>2022</b> , 6, 44-49	1.8	
8	The effect of nigella sativa supplementation on cardiometabolic outcomes in patients with non-alcoholic fatty liver: A randomized double-blind, placebo-controlled trial.. <i>Complementary Therapies in Clinical Practice</i> , <b>2022</b> , 48, 101598	3.5	○
7	Sex hormone binding globulin as a potential drug candidate for liver-related metabolic disorders treatment. <i>Biomedicine and Pharmacotherapy</i> , <b>2022</b> , 153, 113261	7.5	○
6	Insight into Potential Interactions of Thyroid Hormones, Sex Hormones and Their Stimulating Hormones in the Development of Non-Alcoholic Fatty Liver Disease. <b>2022</b> , 12, 718		○
5	Risk Prevention and Health Promotion for Non-Alcoholic Fatty Liver Diseases (NAFLD). <b>2022</b> , 2, 264-282		○
4	Clearing Steatosis Prior to Liver Surgery for Colorectal Metastasis: A Narrative Review and Case Illustration. <b>2022</b> , 14, 5340		○
3	The Evidence Surrounding Non-Alcoholic Fatty Liver Disease in Individuals with Cancer: A Systematic Literature Review. <b>2023</b> , 30, 48-74		○
2	The Influence of Ambient Temperature on Adipose Tissue Homeostasis, Metabolic Diseases and Cancers. <b>2023</b> , 12, 881		○
1	Lipid accumulation product (LAP) index for the diagnosis of nonalcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis. <b>2023</b> , 22,		○